×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Investment: Amyloid Therapeutics: Investment Landscape Analysis
investment
949 words
KG: amyloid
Contents
Amyloid Therapeutics: Investment Landscape Analysis
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (177)
...
Score: 0.68
Complement C1QA Spatial Gradient in Cortical Layers
Score: 0.68
Excitatory Neuron Vulnerability via SLC17A7 Downregulation
Score: 0.67
RAB27A-dependent extracellular vesicle engineering for mitoc
Score: 0.67
Metabolic Reprogramming via Microglial Glycolysis Inhibition
Score: 0.67
Partial Neuronal Reprogramming via Modified Yamanaka Cocktai
Score: 0.67
Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain A
Score: 0.67
Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli
Score: 0.67
Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu
Score: 0.67
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.67
GAP43-mediated tunneling nanotube stabilization enhances neu
Score: 0.67
Complement C1q Subtype Switching
Score: 0.66
Biorhythmic Interference via Controlled Sleep Oscillations
Score: 0.66
Temporal TET2-Mediated Hydroxymethylation Cycling
Score: 0.66
Mitochondrial RNA Granule Rescue Pathway
Score: 0.66
Optogenetic Microglial Deactivation via Engineered Inhibitor
Score: 0.66
Arginine Methylation Enhancement Therapy
Score: 0.65
KDM6A-Mediated H3K27me3 Rejuvenation
Score: 0.65
Microbial Inflammasome Priming Prevention
Score: 0.65
Nucleolar Stress Response Normalization
Score: 0.65
← Prev
pg 6/9
Next →
Related Analyses (30)
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · completed
Astrocyte Reactivity Subtypes in Neurodegeneration
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
Mitochondrial transfer between neurons and glia
neurodegeneration · completed
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · completed
Show 25 more
Related Experiments (27)
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Spinocerebellar Ataxia (SCA) Disease-Modifying Therapy Devel
validation · proposed · Score: 0.40
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
Down Syndrome Alzheimer's Disease: Mechanisms and Therapeuti
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Vascular Contribution to Alzheimer's Disease — Beyond Amyloi
validation · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti
clinical · proposed · Score: 0.40
Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?
clinical · proposed · Score: 0.40
Longitudinal TLR2 reporter gene study in α-synuclein mice
validation · proposed · Score: 0.90
Leukocyte gene expression analysis in COVID-19 patients
exploratory · proposed · Score: 0.90
RBG treatment in ApoE-/- atherosclerosis mouse model
validation · proposed · Score: 0.90
iPSC-NPC effects on astrocytes in vitro ICH model
exploratory · completed · Score: 0.90
Dexamethasone treatment study in α-synuclein mice
validation · proposed · Score: 0.85
TLR expression in α-synuclein overexpressing mice
validation · proposed · Score: 0.80
NLRP3 Inflammasome Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Show 22 more
See Also (15)
ABI3 Gene
gene · KG edge: activates
ABCA7 (Redirect)
redirect · KG edge: activates
ABCA1 - ATP-Binding Cassette Transporter A1
gene · KG edge: activates
ACE Gene
gene · KG edge: activates
A2M Gene
gene · KG edge: interacts_with
Phase 3 Study to Compare the Efficacy and Safety of Mas
clinical · Pages share 4 hypotheses
Digital Therapeutic Platform for Swallowing and Droolin
clinical_trial · Pages share 4 hypotheses
Synaptic Therapy Alzheimer's Research Trial (START): A
clinical · Pages share 4 hypotheses
Cell-Free DNA Biomarkers in Neurodegeneration
biomarker · Pages share 4 hypotheses
Metabolomic Biomarkers in Neurodegeneration
biomarker · Pages share 4 hypotheses
Neuroimaging Biomarkers for Neurodegeneration
biomarker · Pages share 4 hypotheses
Exosomal Biomarkers in Neurodegeneration
biomarker · Pages share 4 hypotheses
Exosomal miR-155 in Neurodegeneration
biomarker · Pages share 4 hypotheses
Utilisation of Health Services and Quality of Life in A
clinical · Pages share 4 hypotheses
Synaptic Biomarkers in Neurodegeneration
biomarker · Pages share 4 hypotheses
Show 10 more
Knowledge Graph (12 edges)
GFAP
associated_with
amyloid
CD33
loss_affects
amyloid
amyloid
causes
cognitive deficits
CX3CR1
co_discussed
amyloid
PARP1
co_discussed
amyloid
TDP43
co_discussed
amyloid
SQSTM1
co_discussed
amyloid
CASP3
co_discussed
amyloid
CLU
co_discussed
amyloid
MS4A6A
co_discussed
amyloid
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.